Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Neurology ; 61(3): 369-74, 2003 Aug 12.
Article in English | MEDLINE | ID: mdl-12913200

ABSTRACT

BACKGROUND: X-linked adrenoleukodystrophy (X-ALD) has variants with widely different outcomes, hampering clinical counseling and evaluation of therapies. OBJECTIVE: To evaluate the degree to which MRI patterns can predict lesion progression. METHODS: Two hundred six boys and men with cerebral X-ALD (median age 12.2 years, mean age 18.5 years, age range 1.7 to 73.8 years) were studied. In 140 individuals, follow-up MRI were available. Data after bone marrow transplantation (BMT) were excluded. The patterns of MRI abnormalities were subdivided into five groups based on the anatomic location of the initial T2 signal hyperintensity (pattern 1: parieto-occipital white matter, pattern 2: frontal white matter, pattern 3: corticospinal tract, pattern 4: cerebellar white matter, pattern 5: concomitant parieto-occipital and frontal white matter). The X-ALD MRI Severity Scale, a 34-point scale previously described, was used in the analysis. RESULTS: Pattern 1 patients had rapid progression if contrast enhancement was present and if the MRI abnormality manifested at an early age. The latter was also true for pattern 2 patients. Based on these variables, predictive formulas were constructed for these two patterns using multiple regressions. MRI progression was much slower in pattern 3 and 4 patients, whereas in the few pattern 5 patients, it was more rapid than in any other of the patterns. Patterns 1 and 5 occurred mainly in childhood, patterns 2 and 4 in adolescence, and pattern 3 in adults. CONCLUSIONS: MRI progression in X-ALD depends on patient age, initial MRI Severity Scale score, and anatomic location of the lesion. When used in combination, these data aid the prediction of disease course and the selection of patients for BMT.


Subject(s)
Adrenoleukodystrophy/diagnosis , Adolescent , Adrenoleukodystrophy/drug therapy , Adult , Age Factors , Aged , Child , Child, Preschool , Disease Progression , Drug Combinations , Erucic Acids/therapeutic use , Follow-Up Studies , Humans , Image Processing, Computer-Assisted , Infant , Linear Models , Magnetic Resonance Imaging , Male , Middle Aged , Predictive Value of Tests , Prognosis , Severity of Illness Index , Triolein/therapeutic use
2.
J Neuroimmunol ; 119(1): 88-94, 2001 Sep 03.
Article in English | MEDLINE | ID: mdl-11525804

ABSTRACT

We analyzed the sera of 51 patients with various phenotypes of X-linked adrenoleukodystrophy (X-ALD), 20 patients with multiple sclerosis (MS) and 22 healthy volunteers for the presence of autoantibodies specific for the recombinant extracellular immunoglobulin-like domain of human myelin oligodendrocyte glycoprotein (rhMOG(Igd)) and myelin basic protein (MBP). Anti-rhMOG(Igd) autoantibodies were significantly more frequent in X-ALD and MS patients as opposed to healthy individuals (p<0.05). Anti-MBP autoantibodies were present in about one-fourth of X-ALD and MS patients but in less than 10% of healthy individuals. Anti-rhMOG(Igd) autoantibody responses were not accompanied by increased T cell reactivity against rhMOG(Igd). These findings may have important implications for the understanding of humoral anti-myelin immunoreactivity in demyelinating diseases of the central nervous system such as X-ALD and MS.


Subject(s)
Adrenoleukodystrophy/genetics , Autoantibodies/blood , Genetic Linkage , Multiple Sclerosis/genetics , Myelin Basic Protein/immunology , Myelin-Associated Glycoprotein/immunology , X Chromosome , Adolescent , Adrenoleukodystrophy/immunology , Adult , Female , Humans , Male , Middle Aged , Multiple Sclerosis/immunology , Myelin Proteins , Myelin-Oligodendrocyte Glycoprotein , Phenotype , Recombinant Proteins/immunology
3.
Ann Neurol ; 49(4): 512-7, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11310629

ABSTRACT

Utilizing the plasma very long chain fatty acid assay, supplemented by mutation analysis and immunofluorescence assay, we determined the number of X-linked adrenoleukodystrophy (X-ALD) hemizygotes from the United States identified each year in the two laboratories that perform most of the assays in this country: the Kennedy Krieger Institute between 1981 and 1998 and the Mayo Clinic Rochester from 1996 to 1998. The minimum frequency of hemizygotes identified in the United States is estimated to be 1:42,000 and that of hemizygotes plus heterozygotes 1:16,800. Our studies involved 616 pedigrees with a total of 12,787 identified at-risk members. Diagnostic assays were performed in 4,169 at-risk persons (33%) and included members of the extended family. Only 5% of male probands and 1.7% of X-ALD hemizygotes were found to have new mutations. The extended family testing led to the identification of 594 hemizygotes and 1,270 heterozygotes. Two hundred fifty of the newly identified hemizygotes were asymptomatic and represent the group in which therapy has the greatest chance of success. Identification of heterozygotes provides the opportunity for disease prevention through genetic counseling. Diagnostic tests should be offered to all at-risk relatives of X-ALD patients and should include members of the extended family.


Subject(s)
Adrenoleukodystrophy/genetics , Genetic Testing , Mutation/genetics , Female , Humans , Male , Pedigree
4.
Ann Neurol ; 49(2): 186-94, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11220738

ABSTRACT

Our objective was to study the phenotype evolution of X-linked adrenoleukodystrophy (X-ALD) and the relation between axonal degeneration and cerebral demyelination. Although different X-ALD phenotypes are recognized, little is known about their evolution. Neuropathological and electrophysiological studies have shown that X-ALD is a disease with mixed features of axonal degeneration, leading to myeloneuropathy, and a severe inflammatory reaction in the cerebral white matter, resulting in demyelination. Retrospectively, 129 men with X-ALD were studied who were 1) at least 20 years presently or at the time of death, and 2) regularly monitored. Phenotype assignments were made at diagnosis and at present, or at death, using medical history and findings of neurological examination. Handicap was studied with the modified Rankin scale, and cerebral abnormalities with the X-ALD MRI severity (Loes) score. The mean follow-up interval was 10.1 +/- 5.0 years. Among 32 patients neurologically asymptomatic at diagnosis, 16 (50%) developed neurological deficits. Among 68 adrenomyeloneuropathy (AMN) patients initially without clinical brain involvement, 13 (19%) additionally developed cerebral demyelination. In a subset of 60 AMN patients, a moderate handicap evolved over a period of 16.2 +/- 8.9 years. Among 13 AMN patients with additional definite or probable cerebral involvement at diagnosis, eight died and one remained in a vegetative state. Most of the 16 patients with the cerebral phenotypes deteriorated. There is a high risk for adult neurologically asymptomatic patients to develop neurological deficits and for AMN patients to develop cerebral demyelination. Axonal degeneration and cerebral demyelination emerge in X-ALD independently of each other. This may have implications for the phenotype classification, the search for modifying factors, and the development and evaluation of new therapies.


Subject(s)
Adrenoleukodystrophy/genetics , Adrenoleukodystrophy/pathology , Phenotype , Adolescent , Adult , Age of Onset , Brain/pathology , Child , Humans , Magnetic Resonance Imaging , Male , Retrospective Studies , Spinal Cord/pathology
5.
J Inherit Metab Dis ; 23(3): 273-7, 2000 May.
Article in English | MEDLINE | ID: mdl-10863943

ABSTRACT

Evaluation of the therapy of X-linked adrenoleukodystrophy (X-ALD) is hampered by its rarity and by the striking and unpredictable variation in phenotypic expression. We present two approaches that may facilitate therapy evaluation. (1) We have analysed data on 377 X-ALD patients who have been followed at the Kennedy Krieger Institute for a mean period of 38 months and have subdivided them into 18 subgroups on the basis of age and the degree of abnormality in brain magnetic resonance imaging (MRI) as assessed by the Loes score (Am. J. Neuroradrol 1994; 15: 1761). We find that grouping on the basis of age and MRI score provides information that is of significant prognostic value. (2) We present plans for the development of a placebo-controlled multicentre international study that will have sufficient biostatistical power to provide objective evaluation of new therapeutic interventions.


Subject(s)
Adrenoleukodystrophy/physiopathology , X Chromosome , Adrenoleukodystrophy/pathology , Age Factors , Clinical Trials as Topic , Humans , Magnetic Resonance Imaging , Multicenter Studies as Topic , Prognosis
6.
Neuropediatrics ; 31(5): 227-39, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11204280

ABSTRACT

The phenotypic expression of X-linked adrenoleukodystrophy (X-ALD) ranges from the rapidly progressive childhood cerebral form to the milder adrenomyeloneuropathy (AMN) in adults. It is not possible to predict phenotype by mutation analysis or biochemical assays. This study reports on 372 patients ranging in age from less than 3 years to adulthood, who have been followed at the Kennedy Krieger Institute. With the aim of determining whether a method could be developed to predict clinical course by analysis of data available at time of first contact, the patients were subdivided into 18 subgroups on the basis of age and the extent of brain magnetic resonance (MRI) abnormality utilizing the MRI scoring system devised by Loes et al. Scores to grade degree of neurologic and neuropsychologic impairment were also developed. There was strong correlation between MRI and the neurology and neuropsychology scores at baseline. Information based exclusively on age and MRI score at time of first contact was highly predictive of future clinical course and should aid the evaluation of the effects of bone marrow transplantation and the selection of patients for this procedure, as well as the evaluation of other therapies that may be developed in the future.


Subject(s)
Adrenoleukodystrophy/diagnosis , Adrenoleukodystrophy/therapy , Bone Marrow Transplantation , Brain/abnormalities , Erucic Acids/therapeutic use , Magnetic Resonance Imaging , Phenotype , Triolein/therapeutic use , Adrenoleukodystrophy/genetics , Adrenoleukodystrophy/pathology , Adult , Age Factors , Age of Onset , Bone Marrow Transplantation/statistics & numerical data , Child , Diagnosis, Differential , Drug Combinations , Female , Follow-Up Studies , Genotype , Humans , Infant, Newborn , Magnetic Resonance Imaging/methods , Male , Prognosis , Prospective Studies , Sex Factors , Treatment Outcome
7.
Neuropediatrics ; 31(6): 293-7, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11508547

ABSTRACT

X-linked adrenoleukodystrophy is a neurodegenerative disorder affecting the myelin of the nervous system and the adrenal cortex. The childhood form of the disease is typically heralded by subtle neurocognitive changes which later progress. Acute presentation of childhood ALD has been reported, but the incidence is not known. We reviewed the records of 485 boys with childhood ALD, determined those with acute presentation, and classified them as adrenal crisis, seizures, or encephalopathy. Of the 485 reviewed cases, 45 (9.3%) presented acutely at an average age of 5.5 years. Twenty of 45 (44%) presented with seizures, focal seizures in 6 boys and generalized in the remainder with 4 having status epilepticus. Twenty out of 45 presented with acute adrenal crisis. Five of 45 presented with acute encephalopathy or coma. The diagnosis of ALD was rarely made in the acute period, but was often suggested by neuroimaging. The accurate, rapid diagnosis of ALD has important implications for treatment as well as for other family members and should be considered in appropriate patients.


Subject(s)
Adrenoleukodystrophy/pathology , Seizures/etiology , Acute Disease , Adrenal Gland Diseases/etiology , Adrenoleukodystrophy/diagnosis , Age of Onset , Child , Child, Preschool , Diagnosis, Differential , Female , Humans , Male , Retrospective Studies
8.
Ann Neurol ; 45(1): 100-10, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9894883

ABSTRACT

The assay of plasma very long chain fatty acids (VLCFAs), developed in our laboratory in 1981, has become the most widely used procedure for the diagnosis of X-linked adrenoleukodystrophy (X-ALD) and other peroxisomal disorders. We present here our 17 years' experience with this assay. Three VLCFA parameters, the level of hexacosanoic acid (C26:0), the ratio of C26:0 to tetracosanoic acid (C24:0), and of C26:0 to docosanoic acid (C22:0), were measured in 1,097 males (hemizygotes) with X-ALD, 1,282 women heterozygous for this disorder, including 379 obligate heterozygotes, 797 patients with other peroxisomal disorders, and 29,600 control subjects. All X-ALD hemizygotes who had not previously received Lorenzo's oil or a diet with a high erucic acid content had increased VLCFA levels, but the application of a discriminant function based on all three measurements is required to avoid the serious consequences of a false-negative result. VLCFA levels are increased at day of birth, thus providing the potential for neonatal mass screening, are identical in the childhood and adult forms, and do not change with age. Eighty-five percent of obligate heterozygotes had abnormally high VLCFA levels, but a normal result does not exclude carrier status. VLCFA levels were increased in all patients homozygous for Zellweger syndrome, neonatal adrenoleukodystrophy, infantile Refsum's disease, and in patients with deficiencies of peroxisomal acyl-coenzyme A oxidase, bifunctional enzyme, and 3-oxoacyl-coenzyme A thiolase. In these patients the degree of VLCFA excess correlated with clinical severity.


Subject(s)
Adrenoleukodystrophy/blood , Fatty Acids/blood , Zellweger Syndrome/blood , Adolescent , Adrenoleukodystrophy/genetics , Adult , Age Factors , Aged , Aged, 80 and over , Child , Child, Preschool , False Negative Reactions , Fatty Acids/genetics , Female , Genetic Testing , Genotype , Heterozygote , Humans , Infant , Infant, Newborn , Male , Microbodies/genetics , Microbodies/metabolism , Middle Aged , Oxidation-Reduction , Phenotype , Zellweger Syndrome/genetics
10.
Ann Neurol ; 31(4): 349-60, 1992 Apr.
Article in English | MEDLINE | ID: mdl-1586135

ABSTRACT

The pathogenesis of central nervous system (CNS) disease in acquired immunodeficiency syndrome (AIDS) is poorly understood but may be related to specific effects of the immune system. Cytokines such as tumor necrosis factor and interleukin-1 may have toxic effects on CNS cells and have been postulated to contribute to the pathogenesis of the neurological complications of human immunodeficiency virus (HIV) infection. To characterize viral and immunological activity in the CNS, frozen specimens taken at autopsy from the cerebral cortex and white matter of HIV-seropositive and -seronegative individuals were stained immunocytochemically for mononuclear cells, major histocompatibility complex (MHC) antigens, HIV, astrocytes, and the cytokines interleukin-1 and -6, tumor necrosis factor-alpha and -beta, and interferon gamma. Levels of soluble CD4, CD8, and interleukin-2 receptor, as well as interferon gamma, tumor necrosis factor-alpha, beta 2-microglobulin, neopterin, and interleukin-6 and -1 beta were assayed in the cerebrospinal fluid and plasma of many of these individuals during life. The HIV-seropositive group included individuals without neurological disease, those with CNS opportunistic infections, and those with HIV encephalopathy. Perivascular cells, consisting primarily of macrophages with some CD4+ and CD8+ T cells and rare B cells, were consistently MHC class II positive. MHC class II antigen was also present on microglial cells, which were frequently positive for tumor necrosis factor-alpha. HIV p24 antigen, when present, was found on macrophages and microglia. Endothelial cells were frequently positive for interleukin-1 and interferon gamma and less frequently for tumor necrosis factor and interleukin-6. There were gliosis and significant increases in MHC class II antigen, interleukin-1, and tumor necrosis factor-alpha in HIV-positive patients compared to HIV-negative brains. Cerebrospinal fluid from most of the patients tested had increased levels of tumor necrosis factor, beta 2-microglobulin, and neopterin. There was no correlation in HIV-positive individuals between levels of cytokines and the presence or absence of CNS disease. These data indicate that there is a relative state of "immune activation" in the brains of HIV-positive compared to HIV-negative individuals, and suggest a potential role for the immune system in the pathogenesis of HIV encephalopathy.


Subject(s)
Acquired Immunodeficiency Syndrome/metabolism , Brain/metabolism , Cytokines/metabolism , Acquired Immunodeficiency Syndrome/immunology , Acquired Immunodeficiency Syndrome/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Astrocytes/pathology , Brain/immunology , Brain/pathology , Child , Child, Preschool , HIV Antigens/analysis , Histocompatibility Antigens Class I/analysis , Histocompatibility Antigens Class II/analysis , Humans , Infant , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...